TD SOLUTIONS ANNOUNCES LEVELLOR™ HYPOSPRAY® INSULIN

Published Monday, June 4, 2018

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--RELEASE PDF  TD Solutions announced today that they have initiated development of Levellor™ HypoSpray Insulin for insulin-dependent diabetics. More than 6 million Americans use insulin in some form and that number will continue to rise. TD Solutions is initiating approval of human insulin 100 & 200 IU/mL delivered via its HypoSpray® system and is seeking a partner interested in licensing this new product entry in a market that is challenged by cost constraints and periodic supply shortages. This system does not employ needles or an injector device. The Insulin is formulated into a liquid carrier composed of substances that are Generally Regarded As Safe (“GRAS”). The formula is absorbed across intact skin, delivering the Insulin as quickly as a hypodermic injection but without the risk and fear of the needle. The spray-on Insulin format has been tested in a preliminary Phase 0 clinical trial and the formula is optimized to perform with injectible insulin products. Due to the elimination of the hypodermic auto-injector, the resulting dose form is so easy to use, a child can self-administer it. TD Solutions will be submitting the results of the preliminary Phase 0 study for peer-review in the near future with a view to publication. The Company will meet for guidance with FDA CDER Office of Generic Drugs (OGD) on the steps for approval of this product and will submit chemistry, manufacturing and controls data as a part of the briefing book. The Company believes that approval could come as early as 2020.

About TD Solutions
TD Solutions is committed to advancing the science of Sprayed-On Pharmaceuticals using its patented system. TD Solutions’ proprietary system enables medications as large as Insulin to be delivered directly through the skin, for systemic or localized application, utilizing its rapid acting, patchless, spray-on technology. The company’s technology is flexible enough to be applicable to a very wide range of compounds for pharmaceutical or cosmetic use. No other company can offer similar, consumer friendly, dosing flexible solutions. https://youtu.be/hYnOl0b5KeE Visit: www.tdsc.us


Contacts
MarCom Consultant (for TDSC)
Cindy Metzler, 561-429-6429 (Headquarters)
cindy@cindymetzler.com
www.tdsc.us


TD Solutions Announces Levellor™ HypoSpray® Insulin TD Solutions, a leader in the development of spray-on pharmaceuticals (SOP™), announced today they have initiated product development for a needle-free Human Insulin product
6/4/2018 TD Solutions Announces Levellor™ HypoSpray® Insulin | Business Wire
https://www.businesswire.com/news/home/20180522006303/en/TD-Solutions-Announces-Levellor%E2%84%A2-HypoSpray%C2%AE-Insulin 2/2

 



Investors

Aerojet Rocketdyne Bank of America BB&T CareerSource Centennial Bank
DePuy Synthes Power Tools, a Johnson & Johnson Company Engel & Volkers Palm Beach Equestrian Center Florida Crystals Corporation FPL
GL Homes GliddenSpina + Partners Greenberg Traurig Gunster Hardrives, Inc.
HCA Palm Beach Hospitals Hedrick Brothers Construction J.C. White JP Morgan Chase LRP Publications
MBAF Minto Communities, LLC NCCI NextGen Mgmt dba DxWeb Management, LLC Nova Southeastern University
Palm Beach Aggregates, LLC Palm Beach County Board of County Commissioners Palm Beach Park of Commerce Pratt & Whitney (A United Technologies Company) Raymond James Financial Services/Boynton Financial Group, Inc.
RSM South Florida Business & Wealth Magazine South Florida Business Journal TD Bank Tortoise Properties
Wells Fargo & Company Wexford Capital